AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Synagis (palivizumab) by Year
Synagis (palivizumab) — International net revenues [legacy through FY20Q1] ($M) ($M)
AbbVie Synagis (palivizumab): $718M in FY2019, down 1.1% from a year earlier. No newer figure appears in the documents we track.
Latest, FY2019
718
Period ended Dec 31, 2019
Change on a year earlier
-1.1%
726 in FY2018
History
4 years
Since FY2016
Sources
2
Documents cited below
Where the FY2019 figure comes from
Source: Form 10-K (filed 2020-02-21) ↗
Reported in Form 10-Q / 10-K Segment Note.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Synagis (palivizumab) — International net revenues [legacy through FY20Q1] ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2019 | Dec 31, 2019 | 718 | -1.1% | Form 10-K (filed 2020-02-21) ↗ |
| FY2018 | Dec 31, 2018 | 726 | -1.6% | Form 10-K (filed 2020-02-21) ↗ |
| FY2017 | Dec 31, 2017 | 738 | +1.1% | Form 10-K (filed 2020-02-21) ↗ |
| FY2016 | Dec 31, 2016 | 730 | – | Form 10-K (filed 2019-02-27) ↗ |
Cite this data
StockData. (2026). AbbVie Synagis (palivizumab) ($M), annual FY2016–FY2019 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/synagis-intl
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.